MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

Search

Sanofi SA

Cerrado

SectorSalud

88.23 0.88

Resumen

Variación precio

24h

Actual

Mínimo

87.47

Máximo

88.42

Métricas clave

By Trading Economics

Ingresos

1.4B

1.9B

Ventas

3B

11B

P/B

Media del Sector

17.216

51.198

BPA

1.79

Rentabilidad por dividendo

4.48

Margen de beneficio

17.65

Empleados

82,878

EBITDA

2.2B

2.8B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+31.16% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.48%

2.40%

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-19B

111B

Apertura anterior

87.35

Cierre anterior

88.23

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

136 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jun 2025, 16:05 UTC

Principales Movimientos del Mercado

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 jun 2025, 09:17 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 jun 2025, 05:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 may 2025, 12:02 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 may 2025, 00:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vigil Neuroscience for About $470 Million

2 jun 2025, 13:50 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 jun 2025, 12:33 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 jun 2025, 10:50 UTC

Adquisiciones, fusiones, absorciones

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 jun 2025, 10:05 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 jun 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 jun 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 jun 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 jun 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 jun 2025, 05:04 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 jun 2025, 05:04 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 jun 2025, 05:03 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Blueprint Medicines Corporation

2 jun 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Acquire Blueprint Medicines Corporation

30 may 2025, 08:58 UTC

Acciones populares

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 may 2025, 08:56 UTC

Charlas de Mercado

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 may 2025, 05:03 UTC

Adquisiciones, fusiones, absorciones

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 may 2025, 05:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 may 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 may 2025, 23:23 UTC

Adquisiciones, fusiones, absorciones

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 may 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 may 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 may 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19 may 2025, 11:01 UTC

Charlas de Mercado

Diversified Exposure to European Banks Is Required -- Market Talk

15 may 2025, 11:04 UTC

Charlas de Mercado
Ganancias

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

31.16% repunte

Estimación a 12 meses

Media 114.266 EUR  31.16%

Máximo 127 EUR

Mínimo 95 EUR

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

12

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

91.3 / 96.1Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

136 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.